疫苗的作用与疫苗决策对实现公共卫生大汇聚目标的意义
2015年7月17日至18日,ADITEC与葛兰素史克(GSK)在锡耶纳联合召开会议,审查《全球健康2035》大汇聚目标、讨论当前疫苗评估方法,并探讨就全面准确捕获疫苗全部益处的评估框架达成共识的可行性。通过讲座和研讨会,参会者达成共识:多准则决策分析适用于系统考量评估疫苗接种广泛益处所需的诸多变量,包括卫生系统节约、家庭获益和生产力提升等社会效益;并同意一套用于未来疫苗研发和引入评估的「核心价值」。
要点
- 多准则决策分析被视为系统评估疫苗广泛益处的适用方法。
- 核心价值包括疫苗效力和安全性、每年预防发病例数、成本效益分析结果、可预防死亡和目标疾病严重程度。
- 就核心评估参数达成一致,有望增进制造商、公共卫生机构、非政府组织和决策者之间的协同。
核心结论
- 参会者共识认为多准则决策分析是系统考量评估疫苗接种广泛益处所需诸多变量的适用方法。
- 参会者同意一套用于未来疫苗研发和引入评估的「核心价值」。
研究设计与样本
- 2015年7月17日至18日,ADITEC与葛兰素史克(GSK)联合在锡耶纳召开会议,通过讲座和研讨会进行讨论。
主要发现
- 疫苗广泛益处不仅包括卫生系统节约,还包括社会效益,含家庭获益和生产力提升。
- 核心价值包括疫苗效力和安全性、每年预防发病例数、成本效益分析结果、可预防死亡和目标疾病严重程度。
- 就核心评估参数达成一致,有望增进制造商、公共卫生机构、非政府组织和决策者之间的协同。
关键数值与推荐
- 第4工作组受命审查从SMART疫苗中选出的24项参数,以确定哪些因素应在评估疫苗对《全球健康2035》大汇聚最大成功的作用时纳入考量。
- 第4工作组受命制定3至5项「核心价值」,用于评估不同研发阶段的疫苗。
- 第4工作组受命确定疫苗如何最好地促进《全球健康2035》大汇聚工作。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On 17 and 18 July 2015, a meeting in Siena jointly sponsored by ADITEC and GlaxoSmithKline (GSK) was held to review the goals of the Global Health 2035 Grand Convergence, to discuss current vaccine evaluation methods, and to determine the feasibility of reaching consensus on an assessment framework for comprehensively and accurately capturing the full benefits of vaccines. Through lectures and workshops, participants reached a consensus that Multi-Criteria-Decision-Analysis is a method suited to systematically account for the many variables needed to evaluate the broad benefits of vaccination, which include not only health system savings, but also societal benefits, including benefits to the family and increased productivity. Participants also agreed on a set of "core values" to be used in future assessments of vaccines for development and introduction. These values include measures of vaccine efficacy and safety, incident cases prevented per year, the results of cost-benefit analyses, preventable mortality, and the severity of the target disease. Agreement on this set of core assessment parameters has the potential to increase alignment between manufacturers, public health agencies, non-governmental organizations (NGOs), and policy makers (see Global Health 2035 Mission Grand Convergence [1]). The following sections capture the deliberations of a workshop (Working Group 4) chartered to: (1) review the list of 24 parameters selected from SMART vaccines (see the companion papers by Timmis et al. and Madhavan et al., respectively) to determine which represent factors (see Table 1) that should be taken into account when evaluating the role of vaccines in maximizing the success of the Global Health 2035 Grand Convergence; (2) develop 3-5 "core values" that should be taken into account when evaluating vaccines at various stages of development; and (3) determine how vaccines can best contribute to the Global Health 2035 Grand Convergence effort.
引用
- Kaslow DC, Kalil J, Bloom D, et al. The role of vaccines and vaccine decision-making to achieve the goals of the Grand Convergence in public health. Vaccine. 2016. PMID: 28017438. doi:10.1016/j.vaccine.2016.10.088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。